Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerd R Burmester

Showing results (121-130 of 335) with videos related to

Pageof 34
Sort By:
Rheumatology International|October 21, 2018
On-drug and drug-free remission by baseline symptom duration: abatacept with methotrexate in patients with early rheumatoid arthritisVivian P Bykerk, Gerd R Burmester, Bernard G Combe, et al.
Annals of the Rheumatic Diseases|April 9, 2017
Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trialGerd R Burmester, William F Rigby, Ronald F van Vollenhoven, et al.
Annals of the Rheumatic Diseases|February 11, 2017
Carbamylation of vimentin is inducible by smoking and represents an independent autoantigen in rheumatoid arthritisCaroline Ospelt, Holger Bang, Eugen Feist, et al.
Arthritis Research & Therapy|March 18, 2006
Decrease in expression of bone morphogenetic proteins 4 and 5 in synovial tissue of patients with osteoarthritis and rheumatoid arthritisCarsten P Bramlage, Thomas Häupl, Christian Kaps, et al.
Arthritis Research & Therapy|November 14, 2009
Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trialVibeke Strand, Philip Mease, Gerd R Burmester, et al.
Rheumatology (Oxford, England)|February 2, 2023
Long-term safety and efficacy of sarilumab with or without background csDMARDs in rheumatoid arthritisGerd R Burmester, Vibeke Strand, Alan J Kivitz, et al.
RMD Open|July 28, 2023
Patient-level factors predictive of interstitial lung disease in rheumatoid arthritis: a systematic reviewEric L Matteson, Marco Matucci-Cerinic, Michael Kreuter, et al.
RMD Open|June 30, 2018
Impact of tocilizumab administered intravenously or subcutaneously on patient-reported quality-of-life outcomes in patients with rheumatoid arthritisVibeke Strand, Margaret Michalska, Christine Birchwood, et al.
Cell and Tissue Research|March 21, 2002
Porcine mesenchymal stem cells. Induction of distinct mesenchymal cell lineagesJochen Ringe, Christian Kaps, Bernhard Schmitt, et al.
The Journal of Rheumatology|October 5, 2010
Anticentromere-A and anticentromere-B antibodies show high concordance and similar clinical associations in patients with systemic sclerosisKatharina Hanke, Mike O Becker, Claudia S Brueckner, et al.
Pageof 34

Showing results (121-130 of 335) with videos related to

Sort By:
Pageof 34
Rheumatology International|October 21, 2018
On-drug and drug-free remission by baseline symptom duration: abatacept with methotrexate in patients with early rheumatoid arthritisVivian P Bykerk, Gerd R Burmester, Bernard G Combe, et al.
Annals of the Rheumatic Diseases|April 9, 2017
Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trialGerd R Burmester, William F Rigby, Ronald F van Vollenhoven, et al.
Annals of the Rheumatic Diseases|February 11, 2017
Carbamylation of vimentin is inducible by smoking and represents an independent autoantigen in rheumatoid arthritisCaroline Ospelt, Holger Bang, Eugen Feist, et al.
Arthritis Research & Therapy|March 18, 2006
Decrease in expression of bone morphogenetic proteins 4 and 5 in synovial tissue of patients with osteoarthritis and rheumatoid arthritisCarsten P Bramlage, Thomas Häupl, Christian Kaps, et al.
Arthritis Research & Therapy|November 14, 2009
Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trialVibeke Strand, Philip Mease, Gerd R Burmester, et al.
Rheumatology (Oxford, England)|February 2, 2023
Long-term safety and efficacy of sarilumab with or without background csDMARDs in rheumatoid arthritisGerd R Burmester, Vibeke Strand, Alan J Kivitz, et al.
RMD Open|July 28, 2023
Patient-level factors predictive of interstitial lung disease in rheumatoid arthritis: a systematic reviewEric L Matteson, Marco Matucci-Cerinic, Michael Kreuter, et al.
RMD Open|June 30, 2018
Impact of tocilizumab administered intravenously or subcutaneously on patient-reported quality-of-life outcomes in patients with rheumatoid arthritisVibeke Strand, Margaret Michalska, Christine Birchwood, et al.
Cell and Tissue Research|March 21, 2002
Porcine mesenchymal stem cells. Induction of distinct mesenchymal cell lineagesJochen Ringe, Christian Kaps, Bernhard Schmitt, et al.
The Journal of Rheumatology|October 5, 2010
Anticentromere-A and anticentromere-B antibodies show high concordance and similar clinical associations in patients with systemic sclerosisKatharina Hanke, Mike O Becker, Claudia S Brueckner, et al.
Pageof 34